A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE
Public ClinicalTrials.gov record NCT00914966. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE® (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objectives of the study were: 1. To assess the safety and tolerability of escalating doses of CINRYZE. 2. To assess the effect of an escalating dose algorithm for CINRYZE on hereditary angioedema (HAE) attack rates. 3. To assess the immunogenicity of CINRYZE.
Study identification
- NCT ID
- NCT00914966
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 20 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 6 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2009 (Actual)
- Primary completion
- May 24, 2012 (Actual)
- Completion
- May 24, 2012 (Actual)
- Last update posted
- Jun 23, 2021
2009 – 2012
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Allergy, Asthma and Immunology Associates | Scottsdale | Arizona | 85251 | — |
| Family Allergy and Asthma Center | Atlanta | Georgia | 30342 | — |
| Institute for Asthma and Allergy | Wheaton | Maryland | 20902 | — |
| Winthrop University Hospital | Mineola | New York | 11501 | — |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45267 | — |
| Allergy and Asthma Research Group | Eugene | Oregon | 97401 | — |
| Baker Allergy, Asthma and Dermatology Research Center | Lake Oswego | Oregon | 97035 | — |
| East Tennessee Center for Clinical Research | Knoxville | Tennessee | 37909 | — |
| Not listed | Bryan | Texas | 77802 | — |
| AARA Research Center | Dallas | Texas | 75231 | — |
| Marycliff Allergy Specialist | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00914966, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 23, 2021 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00914966 live on ClinicalTrials.gov.